Lean PCOS/PMOS: When You're Not Overweight But Still Have the Condition

What "lean PMOS" actually means

There is no separate disease. "Lean PMOS" simply describes patients meeting standard diagnostic criteria who have a BMI in the normal range. The underlying mechanisms are the same, though the emphasis differs.

What is typically similar or identical to higher-BMI PMOS:

• Ovulatory dysfunction and its consequences for fertility
• Hyperandrogenism — hirsutism, acne, androgenic alopecia
• Elevated AMH and polycystic ovarian morphology
• Neuroendocrine disturbance with raised LH:FSH ratio, which is often more pronounced in lean patients
• Elevated cardiometabolic risk relative to weight-matched women without PMOS

What is typically different:

• Insulin resistance is generally less severe, but is still present in a substantial proportion — it does not disappear with a normal BMI
• Visceral (intra-abdominal) fat may be raised despite normal total body weight and normal appearance — the "normal weight central obesity" or metabolically obese normal weight phenotype
• Adrenal androgen contribution (DHEAS) is often relatively more prominent

The critical clinical inference: a normal BMI does not license you to skip metabolic screening.

---

Why lean patients get missed

The weight anchor. When weight gain is absent, clinicians commonly look for another explanation for oligomenorrhoea — stress, thyroid, "just irregular cycles" — and the syndrome is not considered.

Hirsutism masked by hair removal. Most patients thread, wax or laser before a consultation. If you ask "do you have excess facial hair?" the answer is often no; if you ask "do you remove facial hair, how often, and since when?" the answer changes. This single question change is the highest-yield adjustment most clinicians can make.

Total testosterone reported as normal. SHBG tends to be less suppressed in lean patients, so total testosterone is more likely to fall in range. If the free androgen index is not calculated, biochemical hyperandrogenism is missed.

Cycles described as "slightly irregular". A 40-day cycle sounds trivial to a patient and is often not volunteered. Under the criteria, cycles longer than 35 days beyond 3 years post-menarche qualify as irregular.

BMI recorded against the wrong reference. Using international rather than Asian-specific cut-offs systematically reclassifies overweight South Asian women as normal.

---

The differential diagnosis matters more in lean patients

This is the key clinical distinction, and getting it wrong causes real harm.

Functional hypothalamic amenorrhoea (FHA) is the principal alternative in a lean woman with absent or very infrequent periods. It arises from energy deficit — restrictive eating, high exercise load, psychological stress — and is mechanistically opposite to PMOS.

The two can coexist, which complicates matters — a woman with underlying PMOS who develops energy deficit may present with a mixed picture.

Why this distinction matters: prescribing a combined oral contraceptive to "regulate" FHA masks the amenorrhoea, provides false reassurance, does not correct the energy deficit, and does not reliably protect bone density. The patient continues losing bone while her chart says her cycles are regular. This is a genuinely harmful error and it is not rare.

Also exclude, as in all patients: thyroid dysfunction, hyperprolactinaemia, non-classic congenital adrenal hyperplasia (morning follicular 17-OHP), primary ovarian insufficiency (raised FSH), and androgen-secreting tumours where virilisation is rapid.

---

Management of lean PMOS

The framework is the same, but the emphasis shifts.

Weight loss is not the goal. This should be stated explicitly to the patient, because many lean patients arrive having read that weight loss is the primary treatment and conclude either that nothing applies to them or that they should restrict further. The latter is actively dangerous.

Exercise still matters — for insulin sensitivity, not weight. Resistance training and moderate aerobic activity improve insulin sensitivity independent of weight change. Frame the goal as metabolic health and cycle regularity.

Diet quality, not restriction. Reducing refined carbohydrate load and improving protein and fibre intake improves glycaemic handling without energy restriction. In an Indian dietary context — typically high in refined grains — this is often achievable without reducing total intake at all.

Metabolic screening is required, not optional. OGTT, fasting lipids, blood pressure, waist circumference. Do not defer these on the basis of a normal BMI.

Combined oral contraceptives remain first-line for cycle regulation and hyperandrogenic symptoms where pregnancy is not currently desired.

Anti-androgens (spironolactone, finasteride) for hirsutism and androgenic alopecia, with reliable contraception, typically after 6 months of COC if response is inadequate.

Metformin may still be appropriate where insulin resistance or impaired glucose tolerance is demonstrated. It is not automatically excluded by a normal BMI.

Inositol is a reasonable consideration given tolerability, with the same caveat that efficacy evidence remains uncertain.

For fertility: letrozole remains first-line for ovulation induction, exactly as in higher-BMI patients. Lean patients often have a favourable response.

Screen for disordered eating and for depression/anxiety. Both are relevant, and the eating disorder screen is specifically important given the FHA differential.

---

For gynaecologists: practice points

Apply Asian-specific BMI cut-offs. Overweight ≥ 23 kg/m², obese ≥ 25 kg/m². Record waist circumference; ≥ 80 cm is the threshold for South Asian women and identifies visceral adiposity that BMI misses entirely.

Ask about hair removal practices, not about excess hair. Frequency, method, and age of onset.

Always calculate the free androgen index. Total testosterone in isolation will under-detect hyperandrogenism, and does so differently in lean versus higher-BMI patients.

Take a dietary and exercise history in every lean patient with oligo-/amenorrhoea before labelling PMOS. Energy deficit is the commonest missed alternative and the consequences of missing it are skeletal.

Order the OGTT anyway. The most consistent gap in real-world care of lean PMOS is absent metabolic screening.

Do not tell a lean patient her PMOS is "mild". It sets an expectation that no long-term monitoring is needed and reduces engagement with follow-up.